← All trials
NCT04317885
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2019
- Primary completion
- Aug 31, 2021
- Completion date
- Aug 31, 2021
- First posted
- Mar 23, 2020
- Last posted
- Mar 23, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologyReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.